PMGC Holdings Inc (ELAB)
PMGC Holdings Inc. is a Nasdaq-listed common stock company focused on biopharmaceutical development and related activities. The business centers on creating and acquiring aesthetic medicines and therapeutic products, with EL-22 highlighted as its lead program. EL-22 is described as an engineered probiotic approach intended to address obesity-related concerns, including preserving muscle during weight loss treatments such as GLP-1 receptor agonists. Alongside product development, the company is involved in medical scientific research and development and also operates investment firms. Based in Newport Beach, California, PMGC Holdings was incorporated in 2020 and adopted its current name in December 2024 after previously operating as Elevai Labs, Inc.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ELAB
|
$2.74
|
66.3% Upside
|
Bargain
|
Not available
|
Not available
|
Weak
|
0.0%
|
November 13, 2026
|
0.1x
|
0.5x
|
1.336 M
|
-3.389 M
|
91.1%
|
94.4%
|
-0.9
|
66.2%
|